ATOS.US Atossa Genetics Inc

Healthcare Health Care Equipment & Supplies USA Stocks
1.96 USD
Close of Nov 13, 2026
1.70 14.85
Market cap
USD 19.6M
P/E
-
P/B
0.89x
ROE
-145.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ATOS.US undervalued?

Graham number

The Graham number of Atossa Genetics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Atossa Genetics Inc fundamental analysis

No fundamental analysis for Atossa Genetics Inc yet.

Atossa Genetics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Atossa Genetics Inc

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Gene…

Full company profile